| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| STAT3 Transcription Factor | 12 | 2023 | 1136 | 1.540 |
Why?
|
| Interleukin-6 | 5 | 2011 | 1053 | 0.870 |
Why?
|
| GPI-Linked Proteins | 6 | 2013 | 232 | 0.860 |
Why?
|
| Janus Kinases | 2 | 2020 | 175 | 0.710 |
Why?
|
| Fibrosis | 2 | 2020 | 735 | 0.680 |
Why?
|
| Naphthols | 2 | 2017 | 27 | 0.670 |
Why?
|
| Pancreatic Neoplasms | 13 | 2013 | 5249 | 0.510 |
Why?
|
| Dendritic Cells | 5 | 2010 | 1109 | 0.490 |
Why?
|
| Cell Proliferation | 9 | 2017 | 7250 | 0.440 |
Why?
|
| src Homology Domains | 2 | 2023 | 133 | 0.390 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2011 | 65 | 0.370 |
Why?
|
| Inflammation | 1 | 2020 | 2524 | 0.350 |
Why?
|
| Sulfonamides | 2 | 2017 | 1932 | 0.350 |
Why?
|
| Cyclin E | 2 | 2008 | 283 | 0.330 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2020 | 1586 | 0.320 |
Why?
|
| NF-kappa B | 3 | 2013 | 1563 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2008 | 252 | 0.290 |
Why?
|
| Membrane Glycoproteins | 2 | 2008 | 1097 | 0.280 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 14628 | 0.270 |
Why?
|
| Cell Line, Tumor | 16 | 2021 | 14808 | 0.270 |
Why?
|
| Cyclophilin A | 1 | 2005 | 24 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 1544 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 1711 | 0.240 |
Why?
|
| Lipopolysaccharide Receptors | 4 | 2010 | 90 | 0.240 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2007 | 770 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 2075 | 0.230 |
Why?
|
| Cation Transport Proteins | 3 | 2010 | 171 | 0.230 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 344 | 0.220 |
Why?
|
| CD40 Ligand | 2 | 2017 | 130 | 0.220 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2007 | 1371 | 0.200 |
Why?
|
| Aspergillosis | 1 | 2024 | 248 | 0.200 |
Why?
|
| Cytokines | 6 | 2024 | 2817 | 0.190 |
Why?
|
| Genetics, Population | 4 | 2003 | 259 | 0.190 |
Why?
|
| Cell Survival | 5 | 2017 | 3064 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 4138 | 0.180 |
Why?
|
| Mucormycosis | 1 | 2022 | 118 | 0.180 |
Why?
|
| Interleukin-2 | 2 | 2024 | 889 | 0.180 |
Why?
|
| Signal Transduction | 4 | 2017 | 12105 | 0.180 |
Why?
|
| Apoptosis | 4 | 2016 | 7763 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5601 | 0.170 |
Why?
|
| Enzyme Activation | 4 | 2017 | 1815 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 499 | 0.170 |
Why?
|
| S Phase | 2 | 2011 | 290 | 0.170 |
Why?
|
| Monocytes | 3 | 2007 | 789 | 0.160 |
Why?
|
| Prodrugs | 1 | 2020 | 226 | 0.150 |
Why?
|
| Tyrphostins | 2 | 2008 | 111 | 0.150 |
Why?
|
| Mice, Nude | 6 | 2016 | 4348 | 0.150 |
Why?
|
| Animals | 19 | 2024 | 62186 | 0.150 |
Why?
|
| Janus Kinase 2 | 2 | 2015 | 754 | 0.140 |
Why?
|
| CD40 Antigens | 1 | 2017 | 106 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 686 | 0.140 |
Why?
|
| Phosphorylation | 4 | 2020 | 4950 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 454 | 0.140 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2016 | 30 | 0.130 |
Why?
|
| Dioxolanes | 1 | 2015 | 51 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 655 | 0.130 |
Why?
|
| Blotting, Western | 5 | 2021 | 3596 | 0.130 |
Why?
|
| RNA, Small Interfering | 3 | 2015 | 2198 | 0.130 |
Why?
|
| Neoplasms | 3 | 2020 | 15891 | 0.130 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 260 | 0.130 |
Why?
|
| Platelet Activation | 1 | 2015 | 100 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 714 | 0.130 |
Why?
|
| Platelet Aggregation | 1 | 2015 | 182 | 0.120 |
Why?
|
| Mice | 14 | 2024 | 35624 | 0.120 |
Why?
|
| Melanoma, Experimental | 1 | 2017 | 382 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2017 | 3907 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1071 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2018 | 333 | 0.120 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 151 | 0.120 |
Why?
|
| MicroRNAs | 3 | 2013 | 2889 | 0.120 |
Why?
|
| Synovial Membrane | 1 | 2014 | 47 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 563 | 0.120 |
Why?
|
| Receptors, KIR | 1 | 2014 | 64 | 0.120 |
Why?
|
| Morpholines | 2 | 2016 | 296 | 0.110 |
Why?
|
| Humans | 36 | 2024 | 270896 | 0.110 |
Why?
|
| DNA | 4 | 2023 | 3056 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 1649 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2015 | 9041 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2016 | 636 | 0.100 |
Why?
|
| Collagen | 1 | 2015 | 727 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 470 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 2 | 2013 | 1077 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 2456 | 0.100 |
Why?
|
| Luciferases, Renilla | 1 | 2011 | 10 | 0.100 |
Why?
|
| Cyclin A | 1 | 2011 | 49 | 0.100 |
Why?
|
| Coumarins | 1 | 2011 | 38 | 0.100 |
Why?
|
| DNA Primers | 2 | 2011 | 1500 | 0.100 |
Why?
|
| Chromones | 1 | 2011 | 121 | 0.100 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 442 | 0.100 |
Why?
|
| Gene Silencing | 3 | 2009 | 827 | 0.100 |
Why?
|
| Tandem Repeat Sequences | 2 | 2002 | 203 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 1111 | 0.100 |
Why?
|
| Lymphocyte Activation | 3 | 2020 | 1723 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 1007 | 0.090 |
Why?
|
| Alleles | 4 | 2014 | 2594 | 0.090 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 3939 | 0.090 |
Why?
|
| Microsatellite Repeats | 2 | 2003 | 629 | 0.090 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 248 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2011 | 475 | 0.090 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2011 | 288 | 0.090 |
Why?
|
| RNA Interference | 2 | 2011 | 1387 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2390 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 1127 | 0.080 |
Why?
|
| Norwalk virus | 1 | 2010 | 169 | 0.080 |
Why?
|
| Genes, Reporter | 1 | 2011 | 820 | 0.080 |
Why?
|
| Protein Transport | 1 | 2011 | 737 | 0.080 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2010 | 196 | 0.080 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 623 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 496 | 0.080 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2017 | 1161 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 964 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 617 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2016 | 3143 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 1558 | 0.080 |
Why?
|
| Cell Differentiation | 4 | 2007 | 4153 | 0.080 |
Why?
|
| India | 5 | 2014 | 313 | 0.080 |
Why?
|
| Cholesterol Esters | 1 | 2007 | 19 | 0.080 |
Why?
|
| Foam Cells | 1 | 2007 | 27 | 0.080 |
Why?
|
| Immunotherapy, Active | 1 | 2008 | 49 | 0.070 |
Why?
|
| Neuropilin-1 | 1 | 2007 | 40 | 0.070 |
Why?
|
| Base Sequence | 2 | 2011 | 5441 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2392 | 0.070 |
Why?
|
| Thymosin | 1 | 2007 | 28 | 0.070 |
Why?
|
| Gene Expression | 2 | 2014 | 3650 | 0.070 |
Why?
|
| Pentoxifylline | 1 | 2007 | 37 | 0.070 |
Why?
|
| Culture Media, Conditioned | 1 | 2007 | 256 | 0.070 |
Why?
|
| Macrophages | 2 | 2010 | 1348 | 0.070 |
Why?
|
| Cyclophilins | 1 | 2006 | 29 | 0.070 |
Why?
|
| Basigin | 1 | 2006 | 20 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2007 | 286 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2017 | 2162 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2007 | 252 | 0.070 |
Why?
|
| Stem Cells | 1 | 2013 | 1231 | 0.070 |
Why?
|
| Curcumin | 1 | 2006 | 119 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 317 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 3029 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2006 | 299 | 0.060 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 1380 | 0.060 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 643 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 537 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2006 | 367 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 4961 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 558 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2008 | 629 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 879 | 0.060 |
Why?
|
| Lentivirus | 1 | 2024 | 164 | 0.060 |
Why?
|
| Aspergillus fumigatus | 1 | 2024 | 136 | 0.050 |
Why?
|
| Cell Line | 2 | 2015 | 5344 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2022 | 1092 | 0.050 |
Why?
|
| Aspergillus | 1 | 2024 | 151 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2008 | 2142 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2022 | 7383 | 0.050 |
Why?
|
| Melanoma | 1 | 2020 | 5596 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2008 | 1036 | 0.050 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 4804 | 0.050 |
Why?
|
| Alkylation | 1 | 2021 | 33 | 0.050 |
Why?
|
| Tyrosine | 1 | 2023 | 509 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 5407 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2021 | 95 | 0.050 |
Why?
|
| Surface Plasmon Resonance | 1 | 2021 | 98 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 1948 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2024 | 715 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 1578 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 7099 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 4955 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2020 | 1182 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2021 | 163 | 0.040 |
Why?
|
| Pregnancy | 1 | 2013 | 8095 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2020 | 195 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 978 | 0.040 |
Why?
|
| Ligands | 1 | 2021 | 1017 | 0.040 |
Why?
|
| Carcinoma | 1 | 2009 | 2611 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2017 | 57 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2024 | 875 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2021 | 1472 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5566 | 0.040 |
Why?
|
| Up-Regulation | 3 | 2010 | 2425 | 0.040 |
Why?
|
| Superoxides | 2 | 2008 | 219 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2017 | 5718 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 3617 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2017 | 186 | 0.040 |
Why?
|
| Cachexia | 1 | 2018 | 165 | 0.030 |
Why?
|
| Binding Sites | 1 | 2021 | 2255 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2014 | 1248 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 4 | 2003 | 3487 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 884 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2020 | 759 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 403 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2017 | 423 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2003 | 2166 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 2347 | 0.030 |
Why?
|
| Genotype | 2 | 2014 | 4266 | 0.030 |
Why?
|
| Octamer Transcription Factor-2 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Valosin Containing Protein | 1 | 2013 | 14 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 2 | 2008 | 884 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 678 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2013 | 88 | 0.030 |
Why?
|
| Caseins | 1 | 2013 | 75 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 495 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2013 | 275 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 12022 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 1492 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 1013 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2014 | 848 | 0.020 |
Why?
|
| Lactation | 1 | 2013 | 236 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 7726 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2013 | 427 | 0.020 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2010 | 21 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2016 | 704 | 0.020 |
Why?
|
| Viral Tropism | 1 | 2010 | 41 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2009 | 5762 | 0.020 |
Why?
|
| Fucosyltransferases | 1 | 2010 | 78 | 0.020 |
Why?
|
| Asthma | 1 | 2018 | 895 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2010 | 113 | 0.020 |
Why?
|
| Progesterone | 1 | 2013 | 711 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2010 | 116 | 0.020 |
Why?
|
| ABO Blood-Group System | 1 | 2010 | 125 | 0.020 |
Why?
|
| Female | 6 | 2020 | 148810 | 0.020 |
Why?
|
| Targeted Gene Repair | 1 | 2009 | 5 | 0.020 |
Why?
|
| Untranslated Regions | 1 | 2009 | 15 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2008 | 5717 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 3500 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 7920 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 681 | 0.020 |
Why?
|
| Estrogens | 1 | 2013 | 812 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 803 | 0.020 |
Why?
|
| Interferon Type I | 1 | 2010 | 282 | 0.020 |
Why?
|
| Anions | 1 | 2008 | 35 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2009 | 116 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2010 | 520 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3395 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 2460 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 5182 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6258 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 1719 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2010 | 591 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2007 | 97 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2008 | 356 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2007 | 6417 | 0.020 |
Why?
|
| Caliciviridae Infections | 1 | 2010 | 317 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 2034 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2008 | 276 | 0.020 |
Why?
|
| RNA, Untranslated | 1 | 2009 | 242 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9469 | 0.020 |
Why?
|
| Virion | 1 | 2008 | 186 | 0.020 |
Why?
|
| Rats | 1 | 2016 | 6556 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 3486 | 0.020 |
Why?
|
| Virus Replication | 1 | 2010 | 772 | 0.020 |
Why?
|
| Male | 6 | 2017 | 128437 | 0.020 |
Why?
|
| Biological Transport | 1 | 2007 | 632 | 0.020 |
Why?
|
| Disease Progression | 2 | 2008 | 6841 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 3217 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 5150 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 470 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2006 | 331 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 2121 | 0.010 |
Why?
|
| Antioxidants | 1 | 2007 | 520 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2014 | 6231 | 0.010 |
Why?
|
| Brain | 1 | 2017 | 4227 | 0.010 |
Why?
|
| Lung | 1 | 2015 | 3297 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 2614 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2009 | 2091 | 0.010 |
Why?
|
| Swine | 1 | 2008 | 1608 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2017 | 3547 | 0.010 |
Why?
|
| Oxygen | 1 | 2008 | 793 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2007 | 2324 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 806 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 692 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 5309 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2477 | 0.010 |
Why?
|
| Mutation | 1 | 2023 | 15904 | 0.010 |
Why?
|
| Transfection | 1 | 2008 | 3119 | 0.010 |
Why?
|
| Forensic Medicine | 1 | 2002 | 18 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 1641 | 0.010 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 1824 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1389 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 4141 | 0.010 |
Why?
|
| Software | 1 | 2009 | 1389 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2009 | 1715 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2007 | 3070 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7917 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 5020 | 0.010 |
Why?
|
| Cell Movement | 1 | 2008 | 2476 | 0.010 |
Why?
|
| Aged | 2 | 2017 | 73259 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 1316 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2007 | 912 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 3202 | 0.010 |
Why?
|
| Middle Aged | 2 | 2017 | 90230 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2009 | 9303 | 0.010 |
Why?
|
| Adult | 2 | 2014 | 81883 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 22495 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 39750 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 3708 | 0.010 |
Why?
|